{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:05:38Z","timestamp":1790697938927,"version":"4.1.0"},"reference-count":24,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of VitreoRetinal Diseases"],"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Many patients with neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), or retinal vein occlusion who have lost copay assistance from the DBA Good Days national charity fund have been forced to switch treatment from branded intravitreal antivascular endothelial growth factor (anti-VEGF) therapy to bevacizumab. This study sought to characterize the short-term impact of these changes on clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This retrospective study included 89 eyes of 69 patients with nAMD, DME, or retinal vein occlusion who transitioned from receiving branded anti-VEGF therapy (aflibercept 2.0 mg or 8.0 mg; faricimab) to bevacizumab. The primary endpoint was changes from baseline in central subfield thickness (CST) after 1, 2, and 3 injections. Secondary endpoints included changes in best-corrected visual acuity (BCVA), intraocular pressure, intraretinal fluid, subretinal fluid, pigment epithelial detachment, injection intervals, predictors of poor outcome (BCVA loss of \u226515 Early Treatment Diabetic Retinopathy Study letters or CST increase of \u226550 \u00b5m), and switchback to branded therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      From baseline to after the third bevacizumab injection, the CST increased from a mean (\u00b1SD) 228.7 \u00b1 52.3 \u00b5m to 271.3 \u00b1 40.0 \u00b5m in the overall cohort (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .004), and from 224.1 \u00b1 50.6 \u00b5m to 268.6 \u00b1 38.5 \u00b5m among nAMD eyes (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .007). The injection interval decreased from a median 8.6 weeks (interquartile range [IQR], 7.0\u201310.9 weeks) preswitch to 7.5 weeks (IQR, 5.3\u20139.5 weeks) after 3 injections (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .001). Fourteen eyes (15.7%) met the criteria for poor outcome, and 15 (16.9%) were switched back to branded therapy. Worsening intraretinal fluid was an early indicator of suboptimal response, and shorter preswitch injection intervals were a predictor of switching back to branded therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Switching from branded anti-VEGF therapy to bevacizumab was associated with anatomic worsening and shorter injection intervals. Shorter preswitch intervals and early postswitch intraretinal fluid changes may help identify patients at risk for poor outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/24741264261477369","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T12:52:09Z","timestamp":1787575929000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Initial Impact of Loss of Copay Assistance From a National Nonprofit Fund on Outcomes of Retinal Disease"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8495-5845","authenticated-orcid":false,"given":"Victor","family":"Bellanda","sequence":"first","affiliation":[{"name":"Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6754-7199","authenticated-orcid":false,"given":"Suraj","family":"Bala","sequence":"additional","affiliation":[{"name":"Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA"},{"name":"Hackensack Meridian School of Medicine, Nutley, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3169-1097","authenticated-orcid":false,"given":"Gabriel","family":"Castilho S. Barbosa","sequence":"additional","affiliation":[{"name":"Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6929-9504","authenticated-orcid":false,"given":"Nitesh","family":"Mohan","sequence":"additional","affiliation":[{"name":"Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4056-6706","authenticated-orcid":false,"given":"Matthew J.","family":"Schulgit","sequence":"additional","affiliation":[{"name":"Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S.","family":"Babiuch","sequence":"additional","affiliation":[{"name":"Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Yuan","sequence":"additional","affiliation":[{"name":"Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananth","family":"Sastry","sequence":"additional","affiliation":[{"name":"Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0458-4181","authenticated-orcid":false,"given":"Katherine E.","family":"Talcott","sequence":"additional","affiliation":[{"name":"Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"McOwen","sequence":"additional","affiliation":[{"name":"Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Igrec","sequence":"additional","affiliation":[{"name":"Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil K.","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5769-0717","authenticated-orcid":false,"given":"Sumit","family":"Sharma","sequence":"additional","affiliation":[{"name":"Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0964-3283","authenticated-orcid":false,"given":"Andrew P.","family":"Schachat","sequence":"additional","affiliation":[{"name":"Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7496-5118","authenticated-orcid":false,"given":"Danny A.","family":"Mammo","sequence":"additional","affiliation":[{"name":"Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.3390\/ph16081140"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2024.12.020"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.02.022"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000424"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414264"},{"key":"e_1_3_2_7_2","article-title":"Comparative efficacy and safety of faricimab and other anti-VEGF therapy for age-related macular degeneration and diabetic macular edema: a systematic review and meta-analysis of randomized clinical trials","volume":"102","author":"Li G","year":"2023","unstructured":"Li G, Zhu N, Ji A. Comparative efficacy and safety of faricimab and other anti-VEGF therapy for age-related macular degeneration and diabetic macular edema: a systematic review and meta-analysis of randomized clinical trials. Medicine (Baltimore). 2023;102:e36370.","journal-title":"Medicine (Baltimore)"},{"key":"e_1_3_2_8_2","unstructured":"Anon. Good days announces limited re-enrollment for co-pay assistance program - The American Society of Retina Specialists. 2025. Accessed April 29 2025. https:\/\/www.asrs.org\/advocacy\/updates\/10402\/good-days-announces-limited-re-enrollment-for-co-pay-assistance-program"},{"key":"e_1_3_2_9_2","unstructured":"Kirkner RM. As copay aid recedes retina treatment \u2018unsustainable.\u2019 Medscape. 2025. Accessed April 2 2026. https:\/\/www.medscape.com\/viewarticle\/copay-aid-recedes-retina-treatment-unsustainable-2025a1000kys"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.124.12.1701"},{"key":"e_1_3_2_11_2","article-title":"Real-world visual acuity outcomes for patients with na\u00efve neovascular age-related macular degeneration treated with aflibercept, ranibizumab, or bevacizumab in the Republic of Korea","volume":"19","author":"Lee YJ","year":"2024","unstructured":"Lee YJ, Kang S, Won JY, et al. Real-world visual acuity outcomes for patients with na\u00efve neovascular age-related macular degeneration treated with aflibercept, ranibizumab, or bevacizumab in the Republic of Korea. PLoS One. 2024;19:e0310381.","journal-title":"PLoS One"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2025.02.002"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00063-1"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02577-1"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2023.12.026"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00010-1"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S409103"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/aos.15783"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000003947"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2023.12.033"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-021-01646-3"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S479816"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2025.06.018"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000003283"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2021.07.026"}],"container-title":["Journal of VitreoRetinal Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24741264261477369","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/24741264261477369","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24741264261477369","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:24:33Z","timestamp":1790695473000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/24741264261477369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":24,"alternative-id":["10.1177\/24741264261477369"],"URL":"https:\/\/doi.org\/10.1177\/24741264261477369","relation":{},"ISSN":["2474-1264","2474-1272"],"issn-type":[{"value":"2474-1264","type":"print"},{"value":"2474-1272","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"article-number":"24741264261477369"}}